Biogen traded at $210.63 this Friday July 1st, increasing $6.69 or 3.28 percent since the previous trading session. Looking back, over the last four weeks, Biogen gained 6.11 percent. Over the last 12 months, its price fell by 39.60 percent. Looking ahead, we forecast Biogen to be priced at 204.92 by the end of this quarter and at 188.71 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 153.80 0.64 0.42% 33.54%
Acadia Pharmaceuticals 14.37 0.28 1.99% -40.86%
Acorda Therapeutics 0.48 0.01 3.20% -89.34%
ALKERMES 30.53 0.74 2.48% 20.67%
Amgen 245.55 2.25 0.92% -1.27%
Bayer 57.24 -0.11 -0.19% 11.30%
Biogen 210.63 6.69 3.28% -39.60%
Bluebird Bio 4.28 0.14 3.38% -86.36%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Esperion Therapeutics 6.45 0.09 1.42% -68.52%
Gilead Sciences 62.36 0.55 0.89% -10.01%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Incyte Corp 77.67 1.70 2.24% -7.07%
Intra Cellular Therapies 55.17 -1.91 -3.35% 30.58%
Eli Lilly 324.71 0.48 0.15% 38.79%
Merck & Co 92.42 1.25 1.37% 17.58%
Moderna Inc 149.95 7.10 4.97% -36.00%
Marinus Pharmaceuticals 4.76 -0.08 -1.65% -74.73%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Novartis 81.65 1.32 1.64% -3.02%
Puma Biotechnology 2.78 -0.07 -2.46% -68.48%
Pfizer 52.31 -0.12 -0.23% 31.66%
PTC Therapeutics 41.85 1.79 4.47% -2.88%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Sanofi 98.34 0.82 0.84% 13.16%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Sangamo BioSciences 4.28 0.14 3.38% -63.45%
Sanofi 51.01 0.98 1.96% -2.60%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Teva Pharmaceutical Industries Ltd 2,746.00 -16.00 -0.58% -14.64%
United Therapeutics 238.00 2.36 1.00% 29.12%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%

Indexes Price Day Year
US500 3845 0 0% -11.47%
USND 11128 99.11 0.90% -23.99%
USNDX 11694 -28.10 -0.24% -20.91%

Biogen
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.